Migraine

Ajovy Injection Approved for Migraine Prevention in Adults

By September 17, 2018

The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period.

Butalbital/APAP Capsules Launched for Complex Tension Headache

By August 01, 2018

The label includes a Boxed Warning describing the risk of hepatotoxicity associated with APAP. Most cases of liver injury were associated with APAP doses >4000mg daily and often involved >1 APAP-containing product.

First-of-its-Kind Migraine Drug Gets FDA Approval

By May 18, 2018

The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).

Novel Nasal Spray for Migraine Attacks to Be FDA Reviewed

By April 02, 2018

DFN-02 was evaluated in a multicenter, double-blind, randomized, placebo-controlled study (N=107) which showed it was effective in treating pain and associated symptoms during a migraine attack and in reducing attack-related functional disability.

Erenumab Effective in Migraine Patients With Multiple Treatment Failures

By January 23, 2018

Aimovig is a fully human monoclonal antibody, designed to selectively block the calcitonin gene-related peptide (CGRP) receptor.

Monthly Galcanezumab Beneficial for Episodic Migraine Prevention

December 19, 2017

The researchers found that, compared to placebo, galcanezumab (120mg) significantly reduced migraine headache days (99.6% posterior probability, −4.8 days).

Migraine Patch Product No Longer Available

By October 20, 2017

Zecuity, launched in September 2015, is a transdermal system that delivers a therapeutic dose via a single-use, battery-powered patch wrapped around the upper arm or thigh.

Device for Migraine Prevention and Treatment Gets FDA Clearance

By September 07, 2017

The non-invasive SpringTMS device is placed at the back of the patient's head where a forced magnetic pulse is delivered to treat an acute attack or to prevent a future migraine onset.